XTL Biopharma Reports H1 2025 Results Amid Shareholder Dispute

TL;DR

XTLB dropped H1 2025 results, still fighting with Social Proxy ex-shareholders.

AI Summary

XTL Biopharmaceuticals Ltd. announced its financial results for the six months ended June 30, 2025, on December 30, 2025. The company is currently involved in a significant dispute with former shareholders of its subsidiary, The Social Proxy, which was previously reported on October 15, 2024. The company's current performance is also being considered in light of this dispute.

Why It Matters

This filing provides an update on XTL Biopharmaceuticals' financial performance and ongoing legal challenges, which could impact investor confidence and the company's future operations.

Risk Assessment

Risk Level: medium — The ongoing significant dispute with former shareholders introduces uncertainty and potential financial liabilities for the company.

Key Players & Entities

• XTL Biopharmaceuticals Ltd. (company) — Filer and subject of the report
• The Social Proxy (company) — Wholly owned subsidiary involved in a dispute
• NASDAQ: XTLB (company) — Stock ticker symbol
• TASE: XTLB.TA (company) — Stock ticker symbol
• October 15, 2024 (date) — Date of previous report on the dispute
• June 30, 2025 (date) — End date for the reported financial period
• December 30, 2025 (date) — Date of the announcement and filing

FAQ

Key Financial Figures

• $2,194 thousand — e following adjustments: an increase of $2,194 thousand in Cost of Services; an increase of $1,
• $1,021 thousand — and in Cost of Services; an increase of $1,021 thousand in Sales and Marketing expenses; and a
• $3,193 thousand — Marketing expenses; and a reduction of $3,193 thousand in Goodwill asset (Impairment expenses)
• $0.15 million — e 30, 2025 XTL reported approximately $0.15 million in cash and cash equivalents and approx
• $0.10 million — and cash equivalents and approximately $0.10 million in marketable securities as of June 30,
• $0.37 million — rities as of June 30, 2025, compared to $0.37 million in cash and cash equivalents and approx
• $0.77 million — and cash equivalents and approximately $0.77 million in marketable securities as of December
• $0.88 million — 31, 2024. The decrease of approximately $0.88 million in cash and cash equivalents and market
• $86 thousand — d credit from banking corporations were $86 thousand as of June 30, 2025, compared to $138 t
• $138 thousand — ousand as of June 30, 2025, compared to $138 thousand as of December 31, 2024. The decrease o
• $52 thousand — s of December 31, 2024. The decrease of $52 thousand in loans and credit from banking corpor
• $37 thousand — period. Warrants, net on the amount of $37 thousand as of June 30, 2025, compared to $1,279
• $1,279 thousand — ousand as of June 30, 2025, compared to $1,279 thousand as of December 31, 2024. The decrease o
• $801 — he acquisition of The Social Proxy, for $801 thousand, and from a decrease in the fa
• $441 thousand — er shareholders of The Social Proxy, of $441 thousand. Warrants on the amount of $0 thousand

Filing Documents

• ea0271177-6k_xtlbio.htm (6-K) — 64KB
• 0001213900-25-126514.txt ( ) — 66KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: December 30, 2025 By: /s/ Noam Band 6

View Full Filing

View this 6-K filing on SEC EDGAR